Nautilus to Measure Proteoforms Driving Alzheimer’s Disease and Cancer in ARPA-H-Funded SEEDS Consortium
Key Highlights
- ➤ARPA-H consortium awarded up to $51.7 million over four years
- ➤Nautilus expects up to $6 million for Voyager Platform deployment
- ➤SEEDS will study tau and EWS::FLI1 proteoforms in Alzheimer’s and Ewing sarcoma
- ➤Nautilus plans approximately 20 proteoform assays by mid-2028
- ➤Voyager field-evaluation unit has generated tau data since early 2025
Expert Statements
Priyanka Joshi, Assistant Professor, Georgetown University School of Medicine, and SEEDS co-lead
“The field knows more today about the downstream effects of protein misfolding than the upstream molecular causes. Nautilus’ Iterative Mapping method is expected to provide an important tool to help us quantify the diverse proteoforms that may drive misfolding in the first place. Within SEEDS, we will apply the method to diseases where early intervention is critical”
Chuankai (Kai) Zhou, Principal Investigator, Buck Institute for Research on Aging, and SEEDS co-lead
“Understanding how protein folding changes patterns that drive disease has been critical in our field”
Chuankai (Kai) Zhou, Principal Investigator, Buck Institute for Research on Aging, and SEEDS co-lead
“The Nautilus Voyager™ Platform is expected to give us a way to quantify how proteoforms contribute to distinct conformational states at high resolution, enabling us to determine how we might preempt disease progression before irreversible damage occurs.”
Parag Mallick, Co-founder and Chief Scientist, Nautilus Biotechnology
“We are excited to bring Iterative Mapping of proteoforms to this ARPA-H-supported effort to help define the critical link between proteoforms, protein misfolding, and disease”
Parag Mallick, Co-founder and Chief Scientist, Nautilus Biotechnology
“We believe that the highly differentiated data from the Nautilus Voyager Platform could unlock a new generation of proteoform-enabled diagnostics and therapeutics.”
SEATTLE, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering intact, single-molecule proteomics approaches, today announced its participation in SEEDS (Sequence-to-disease: Environment-aware Ensembles of Disordered proteins at Scale), a four-year, multi-center research consortium awarded up to $51.7 million by the Advanced Research Projects Agency for Health (ARPA-H). The consortium, which is co-led by the Buck Institute for Research on Aging and Georgetown University, aims to predict how disease-causing proteins misfold before irreversible damage occurs, and to use those predictions to develop new ways of detecting, slowing, and treating neurodegenerative diseases and cancer. Nautilus expects to receive up to $6 million over the duration of the program to deploy its Voyager Platform to measure proteoforms – the distinct versions of proteins that drive function – from model systems, disease tissues, and biofluids, starting with Alzheimer’s disease and Ewing sarcoma.
Get started
Create a free account to read the full story.